Drug and Device Development Headlines

  • Cytokinetics sinks on abandoning ALS drug after failed trial

    (Reuters) - Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

    in.reuters.com
  • Cytokinetics abandons ALS drug after failed trial, shares tank

    (Reuters) - Cytokinetics Inc will stop developing one of its treatments for ALS, which afflicts Stephen Hawking, after the drug failed in a late-stage trial, the company said on Tuesday, sending its shares tumbling about 35 percent.

    in.reuters.com
  • Cytokinetics abandons ALS drug after failed trial

    (Reuters) - Cytokinetics Inc said on Tuesday it would discontinue developing its drug to treat ALS, a fatal neuro-degenerative disorder, after the treatment failed in a late-stage trial.

    in.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host two EU agencies that must leave London because of Brexit after an extraordinary ministerial meeting in Brussels that left both results decided by drawing lots from a fishbowl.

    in.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host two EU agencies that must leave London because of Brexit after an extraordinary ministerial meeting in Brussels that left both results decided by drawing lots from a fishbowl.

    in.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host two EU agencies that must leave London because of Brexit after an extraordinary ministerial meeting in Brussels that left both results decided by drawing lots from a fishbowl.

    www.reuters.com